



MARFAN Links: [Parents/Patients](#) [Healthcare Providers](#) [Contact Info](#) [Brochures](#) [Partners](#)



Print PDF of  
this page




Download  
PDF Reader

## Marfan Study Basics

The Marfan Trial tests Beta Blocker (BB) Therapy (Atenolol) vs. Angiotensin II Receptor B locker (ARB) Therapy (Losartan) in Individuals with Marfan Syndrome (MFS). The trial will enroll 604 participants, 6 months to 25 years of age. Recruitment began in February 2007 and the trial will be completed in approximately 7 years.

## Study Design

A Phase III, *randomized*  , multi-center trial to compare the effect of BB therapy to that of ARB therapy on rate of change in aortic growth and progression of aortic regurgitation in individuals with MFS. Patients are followed for three years after randomization.

## Primary Endpoint

Rate of change in aortic root Z-score adjusted for body surface area.

## Secondary Endpoints

1. Frequency of combined endpoint: aortic dissection, aortic root surgery or death
2. Rate of change of mitral regurgitation
3. Rate of progression of left ventricular dilation and dysfunction
4. Rate of change in central aortic stiffness indices
5. Long bone overgrowth and weight gain
6. Comparison of adverse drug reactions between groups

## Inclusion Criteria


1. 6 months to 25 years of age
2. Diagnosis of MFS according to Ghent criteria
3. Aortic root Z-score >3.0

## Exclusion Criteria

1. Prior aortic surgery
2. Aortic root dimension at the sinuses of Valsalva >5 cm.
3. Planned aortic surgery within 6 months of enrollment

 = glossary definition

4. Aortic dissection
5. Shprintzen-Goldberg syndrome
6. Loeys-Dietz syndrome
7. Therapeutic rather than prophylactic use of ACE-I, BB, or calcium channel blocker (e.g. for arrhythmia, ventricular dysfunction or valve regurgitation)
8. History of angioedema while taking ACE-I or BB
9. Intolerance to losartan or other ARB that resulted in termination of therapy
10. Intolerance to atenolol or other BB that resulted in termination of therapy
11. Renal dysfunction
12. Asthma of sufficient severity to preclude use of a BB
13. Diabetes mellitus
14. Pregnancy or planned pregnancy within 36 months of enrollment
15. Inability to complete study procedures including history of poor acoustic windows (inability to obtain accurate measurement of aortic root)

 [For Patients and Parents](#)

[Who to Contact](#) 

Adjust Text




Department of Health and Human Services



National Institutes of Health



National Heart, Lung, and Blood Institute



Please disable any pop-up blockers to take full advantage of all of the features of this website.  
Last updated: June 2, 2010 10:42 AM